Lanosterol synthase deficiency promotes tumor progression by orchestrating PDL1-dependent tumor immunosuppressive microenvironment

Abstract

Lipid metabolic reprogramming is closely related to tumor progression with the mechanism not fully elucidated. Here, we report the immune-regulated role of lanosterol synthase (LSS), an essential enzyme in cholesterol synthesis. Database analysis and clinical sample experiments suggest that LSS was lowly expressed in colon and breast cancer tissues, which indicates poor prognosis. The biological activity of tumor cell lines and tumor progression in NOD scid gamma (NSG) mice were not affected after LSS knockdown, whereas LSS deficiency obviously aggravated tumor burden in fully immunized mice. Flow cytometry analysis showed that LSS knockdown significantly promoted the formation of tumor immunosuppressive microenvironment, characterized by the increase in M2 macrophages and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as the decrease in anti-tumoral T lymphocytes. With the inhibition of myeloid infiltration or loss function of T lymphocytes, the propulsive effect of LSS knockdown on tumor progression disappeared. Mechanistically, LSS knockdown increased programmed death ligand 1 (PDL1) protein stability by 2,3-oxidosqualene (OS) binding to PDL1 protein. Anti-PDL1 therapy abolished LSS deficiency-induced immunosuppressive microenvironment and cancer progression. In conclusion, our results show that LSS deficiency promotes tumor progression by establishing an OS–PDL1 axis-dependent immunosuppressive microenvironment, indicative of LSS or OS as a potential hallmark of response to immune checkpoint blockade.

Keywords

lanosterol synthase / programmed cell death ligand 1 / tumor immunity / tumor microenvironment

References

1	I Martinez-Reyes, NS Chandel. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669-680.
2	LWS Finley. What is cancer metabolism? Cell. 2023;186(8):1670-1688.
3	D Hanahan, RA Weinberg. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
4	NN Pavlova, J Zhu, CB Thompson. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355-377.
5	L Xia, L Oyang, J Lin, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.
6	LA Broadfield, AA Pane, A Talebi, JV Swinnen, SM Fendt. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56(10):1363-1393.
7	X Bian, R Liu, Y Meng, D Xing, D Xu, Z Lu. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606.
8	J Ou, H Miao, Y Ma, et al. Loss of Abhd5 promotes colorectal tumor development and progression by inducing aerobic glycolysis and epithelial-mesenchymal transition. Cell Rep. 2018;24(10):2795-2797.
9	D Zhang, R Shi, W Xiang, et al. The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages. Signal Transduct Target Ther. 2020;5(1):24.
10	B Huang, BL Song, C Xu. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132-141.
11	OF Kuzu, MA Noory, GP Robertson. The role of cholesterol in cancer. Cancer Res. 2016;76(8):2063-2070.
12	RH Pokhrel, S Acharya, JH Ahn, et al. AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway. Mol Cancer. 2021;20(1):133.
13	P Sharma, S Goswami, D Raychaudhuri, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023;186(8):1652-1669.
14	G Morad, BA Helmink, P Sharma, JA Wargo. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022;185(3):576.
15	DB Johnson, CA Nebhan, JJ Moslehi, JM Balko. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254-267.
16	C Coutzac, JM Jouniaux, A Paci, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020;11(1):2168.
17	Y Yang, JM Hsu, L Sun, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29(1):83-86.
18	JL Gaylor. Membrane-bound enzymes of cholesterol synthesis from lanosterol. Biochem Biophys Res Commun. 2002;292(5):1139-1146.
19	S Hegde, AM Leader, M Merad. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875-884.
20	V Bronte, MJ Pittet. The spleen in local and systemic regulation of immunity. Immunity. 2013;39(5):806-818.
21	Y Pan, Y Yu, X Wang, T Zhang. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084.
22	M Feng, W Jiang, BYS Kim, CC Zhang, YX Fu, IL Weissman. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568-586.
23	NP Restifo, ME Dudley, SA Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281.
24	LB Ivashkiv. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545-558.
25	W Yang, Y Bai, Y Xiong, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651-655.
26	P Goossens, J Rodriguez-Vita, A Etzerodt, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29(6):1376-1389.e4.
27	H Xu, S Zhou, Q Tang, H Xia, F Bi. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188394.
28	W Jiang, JW Hu, XR He, WL Jin, XY He. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.
29	AVR Kornepati, RK Vadlamudi, TJ Curiel. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174-189.
30	L Ai, A Xu, J Xu. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33-59.
31	SR Gordon, RL Maute, BW Dulken, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495-499.